PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22863914-1	2012	Tamibarotene (Am80), a synthetic retinoid approved in Japan for treatment of acute promyelocytic leukemia (APL), is a retinoic acid receptor (RAR) agonist with high specificity for RARalpha and RARbeta over RARgamma.	tamibarotene	0-12	retinoic acid receptor, alpha	Rattus norvegicus	142-145	
22863914-1	2012	Tamibarotene (Am80), a synthetic retinoid approved in Japan for treatment of acute promyelocytic leukemia (APL), is a retinoic acid receptor (RAR) agonist with high specificity for RARalpha and RARbeta over RARgamma.	tamibarotene	0-12	retinoic acid receptor, alpha	Rattus norvegicus	181-189	
22863914-1	2012	Tamibarotene (Am80), a synthetic retinoid approved in Japan for treatment of acute promyelocytic leukemia (APL), is a retinoic acid receptor (RAR) agonist with high specificity for RARalpha and RARbeta over RARgamma.	tamibarotene	0-12	retinoic acid receptor, alpha	Rattus norvegicus	194-201	
22863914-1	2012	Tamibarotene (Am80), a synthetic retinoid approved in Japan for treatment of acute promyelocytic leukemia (APL), is a retinoic acid receptor (RAR) agonist with high specificity for RARalpha and RARbeta over RARgamma.	tamibarotene	14-18	retinoic acid receptor, alpha	Rattus norvegicus	142-145	
22863914-1	2012	Tamibarotene (Am80), a synthetic retinoid approved in Japan for treatment of acute promyelocytic leukemia (APL), is a retinoic acid receptor (RAR) agonist with high specificity for RARalpha and RARbeta over RARgamma.	tamibarotene	14-18	retinoic acid receptor, alpha	Rattus norvegicus	181-189	
22863914-1	2012	Tamibarotene (Am80), a synthetic retinoid approved in Japan for treatment of acute promyelocytic leukemia (APL), is a retinoic acid receptor (RAR) agonist with high specificity for RARalpha and RARbeta over RARgamma.	tamibarotene	14-18	retinoic acid receptor, alpha	Rattus norvegicus	194-201